Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$173.39
Seasonality move
:
-2.9%
Day range:
$169.36 - $174.00
52-week range:
$95.49 - $182.99
Dividend yield:
0%
P/E ratio:
15.09x
P/S ratio:
2.55x
P/B ratio:
2.66x
Volume:
1.3M
Avg. volume:
894.4K
1-year change:
27.38%
Market cap:
$10.5B
Revenue:
$4.1B
EPS (TTM):
-$6.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.51 | 10.99% | 109.38% | $219.40 |
|
ALKS
Alkermes Plc
|
$380.4M | $0.43 | 18.02% | 57.78% | $43.81 |
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | 1.39% | -100% | $12.00 |
|
MDT
Medtronic Plc
|
$8.9B | $1.34 | 8.08% | 104.18% | $111.77 |
|
PRGO
Perrigo Co. Plc
|
$1.1B | $0.79 | 1.55% | 5557.8% | $21.00 |
|
STE
STERIS Plc (Ireland)
|
$1.5B | $2.53 | 7.77% | 85.76% | $281.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$173.25 | $219.40 | $10.5B | 15.09x | $0.00 | 0% | 2.55x |
|
ALKS
Alkermes Plc
|
$32.19 | $43.81 | $5.3B | 15.93x | $0.00 | 0% | 3.56x |
|
AMRN
Amarin Corp. Plc
|
$15.63 | $12.00 | $324.9M | -- | $0.00 | 0% | 8.15x |
|
MDT
Medtronic Plc
|
$98.61 | $111.77 | $126.4B | 27.50x | $0.71 | 2.87% | 3.58x |
|
PRGO
Perrigo Co. Plc
|
$14.55 | $21.00 | $2B | -- | $0.29 | 7.97% | 0.47x |
|
STE
STERIS Plc (Ireland)
|
$247.11 | $281.25 | $24.2B | 34.19x | $0.63 | 1% | 4.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.201 | 67.81% | 1.24x |
|
ALKS
Alkermes Plc
|
3.97% | 0.553 | 1.45% | 3.09x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.914 | 1.98% | 2.35x |
|
MDT
Medtronic Plc
|
37.43% | 0.302 | -- | 1.50x |
|
PRGO
Perrigo Co. Plc
|
46.25% | 0.161 | 124.88% | 0.97x |
|
STE
STERIS Plc (Ireland)
|
22.3% | 0.079 | 8.25% | 1.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
MDT
Medtronic Plc
|
$5.9B | $1.8B | 6.01% | 9.84% | 19.66% | $2.3B |
|
PRGO
Perrigo Co. Plc
|
$377.5M | $106.9M | -0.34% | -0.66% | 10.25% | $29.8M |
|
STE
STERIS Plc (Ireland)
|
$655.1M | $276.9M | 7.93% | 10.4% | 18.51% | $199.5M |
Jazz Pharmaceuticals Plc vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 21%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Alkermes Plc's return on equity of 22.16%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B ALKSAlkermes Plc86.56% $0.49 $1.8B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a consensus price target of $219.40, signalling upside risk potential of 26.64%. On the other hand Alkermes Plc has an analysts' consensus of $43.81 which suggests that it could grow by 36.11%. Given that Alkermes Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc9 1 0 ALKSAlkermes Plc11 3 0 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Alkermes Plc has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.612%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Alkermes Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Alkermes Plc quarterly revenues of $394.2M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Alkermes Plc's net income of $82.8M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Alkermes Plc's PE ratio is 15.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.55x versus 3.56x for Alkermes Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.55x 15.09x $1.1B $251.4M ALKSAlkermes Plc3.56x 15.93x $394.2M $82.8M
-
Which has Higher Returns JAZZ or AMRN?
Amarin Corp. Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of -15.58%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a consensus price target of $219.40, signalling upside risk potential of 26.64%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -23.22%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc9 1 0 AMRNAmarin Corp. Plc0 1 1 -
Is JAZZ or AMRN More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.111%.
-
Which is a Better Dividend Stock JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AMRN?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Amarin Corp. Plc quarterly revenues of $49.4M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.55x versus 8.15x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.55x 15.09x $1.1B $251.4M AMRNAmarin Corp. Plc8.15x -- $49.4M -$7.7M
-
Which has Higher Returns JAZZ or MDT?
Medtronic Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 12.75%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Medtronic Plc's return on equity of 9.84%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B MDTMedtronic Plc64.89% $0.89 $78B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals Plc has a consensus price target of $219.40, signalling upside risk potential of 26.64%. On the other hand Medtronic Plc has an analysts' consensus of $111.77 which suggests that it could grow by 13.35%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Medtronic Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Medtronic Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc9 1 0 MDTMedtronic Plc14 12 0 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.709, suggesting its less volatile than the S&P 500 by 29.108%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic Plc offers a yield of 2.87% to investors and pays a quarterly dividend of $0.71 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Medtronic Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are smaller than Medtronic Plc quarterly revenues of $9B. Jazz Pharmaceuticals Plc's net income of $251.4M is lower than Medtronic Plc's net income of $1.2B. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Medtronic Plc's PE ratio is 27.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.55x versus 3.58x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.55x 15.09x $1.1B $251.4M MDTMedtronic Plc3.58x 27.50x $9B $1.2B
-
Which has Higher Returns JAZZ or PRGO?
Perrigo Co. Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 1.22%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Perrigo Co. Plc's return on equity of -0.66%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B PRGOPerrigo Co. Plc36.19% $0.05 $8.3B -
What do Analysts Say About JAZZ or PRGO?
Jazz Pharmaceuticals Plc has a consensus price target of $219.40, signalling upside risk potential of 26.64%. On the other hand Perrigo Co. Plc has an analysts' consensus of $21.00 which suggests that it could grow by 44.33%. Given that Perrigo Co. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Perrigo Co. Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc9 1 0 PRGOPerrigo Co. Plc2 3 0 -
Is JAZZ or PRGO More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison Perrigo Co. Plc has a beta of 0.391, suggesting its less volatile than the S&P 500 by 60.882%.
-
Which is a Better Dividend Stock JAZZ or PRGO?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co. Plc offers a yield of 7.97% to investors and pays a quarterly dividend of $0.29 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Perrigo Co. Plc pays out 94.9% of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or PRGO?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Perrigo Co. Plc quarterly revenues of $1B. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Perrigo Co. Plc's net income of $12.7M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Perrigo Co. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.55x versus 0.47x for Perrigo Co. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.55x 15.09x $1.1B $251.4M PRGOPerrigo Co. Plc0.47x -- $1B $12.7M
-
Which has Higher Returns JAZZ or STE?
STERIS Plc (Ireland) has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 12.99%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat STERIS Plc (Ireland)'s return on equity of 10.4%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B STESTERIS Plc (Ireland)43.78% $1.96 $9.2B -
What do Analysts Say About JAZZ or STE?
Jazz Pharmaceuticals Plc has a consensus price target of $219.40, signalling upside risk potential of 26.64%. On the other hand STERIS Plc (Ireland) has an analysts' consensus of $281.25 which suggests that it could grow by 13.82%. Given that Jazz Pharmaceuticals Plc has higher upside potential than STERIS Plc (Ireland), analysts believe Jazz Pharmaceuticals Plc is more attractive than STERIS Plc (Ireland).
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc9 1 0 STESTERIS Plc (Ireland)3 2 0 -
Is JAZZ or STE More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.260, which suggesting that the stock is 73.986% less volatile than S&P 500. In comparison STERIS Plc (Ireland) has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.006%.
-
Which is a Better Dividend Stock JAZZ or STE?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. STERIS Plc (Ireland) offers a yield of 1% to investors and pays a quarterly dividend of $0.63 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. STERIS Plc (Ireland) pays out 35.14% of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or STE?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are smaller than STERIS Plc (Ireland) quarterly revenues of $1.5B. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than STERIS Plc (Ireland)'s net income of $194.4M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while STERIS Plc (Ireland)'s PE ratio is 34.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.55x versus 4.19x for STERIS Plc (Ireland). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.55x 15.09x $1.1B $251.4M STESTERIS Plc (Ireland)4.19x 34.19x $1.5B $194.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
ACLX alert for Feb 24
Arcellx, Inc. [ACLX] is up 0.07% over the past day.
Buy
73
HYMC alert for Feb 24
Hycroft Mining Holding Corp. [HYMC] is up 0.64% over the past day.
Sell
39
SCL alert for Feb 24
Stepan Co. [SCL] is up 2.28% over the past day.
